Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany

Background: Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient popula-tions underrepresented in clinical trials, e.g. immunocompromised patients. Additionally, it is not well known to what extent SARS-CoV-2 treatment with monoclonal antibodies could trigger the selection of immune escape viral variants. Methods: After identifying immunocompromised patients with viral rebound under treatment with bam-lanivimab, we characterized the SARS-CoV-2-isolates by whole genome sequencing. Viral load measure-ments and sequence analysis were performed consecutively before and after bamlanivimab administration. Findings: After initial decrease of viral load, viral clearance was not achieved in five of six immunocompro-mised patients treated with bamlanivimab. Instead, viral replication increased again over the course of the following one to two weeks. In these five patients, the E484K substitution -known to confer immune escape -was detected at the time of viral rebound but not before bamlanivimab treatment. Interpretation: Treatment of SARS-CoV-2 with bamlanivimab in immunocompromised patients results in the rapid development of immune escape variants in a significant proportion of cases. Given that the E484K mutation can hamper natural immunity, the effectiveness of vaccination as well as antibody-based therapies, these findings may have important implications not only for individual treatment decisions but may also pose a risk to general prevention and treatment strategies. Funding: All authors are employed and all expenses covered by governmental, federal state, or other publicly funded institutions. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)